Theriva Biologics, Inc. (TOVX)
NYSEAMERICAN: TOVX · Real-Time Price · USD
0.5600
+0.0425 (8.21%)
At close: May 13, 2025, 4:00 PM
0.5941
+0.0341 (6.09%)
Pre-market: May 14, 2025, 6:37 AM EDT
Theriva Biologics Employees
Theriva Biologics had 22 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
22
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,166,045
Market Cap
1.56M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
TOVX News
- 5 days ago - Theriva Biologics Announces Closing of $7.5 Million Public Offering - GlobeNewsWire
- 6 days ago - Theriva Biologics Announces Pricing of $7.5 Million Public Offering - GlobeNewsWire
- 4 weeks ago - Theriva Biologics Announces Presentation of Data from the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients - GlobeNewsWire
- 7 weeks ago - Theriva™ Biologics to Present at the 2025 NeauxCancer Conference - GlobeNewsWire
- 2 months ago - Theriva™ Biologics Reports Full-Year 2024 Operational Highlights and Financial Results - GlobeNewsWire
- 2 months ago - Theriva™ Biologics to Participate in the Q1 Investor Summit Virtual - GlobeNewsWire
- 5 months ago - Theriva™ Biologics Announces U.S. FDA Guidance on Design of Phase 3 Study of VCN-01 for the Treatment of Metastatic Pancreatic Cancer - GlobeNewsWire
- 7 months ago - Theriva Biologics Announces Orphan Medicinal Product Designation Granted by the European Commission to VCN-01 for the Treatment of Retinoblastoma - GlobeNewsWire